Volume 31, Issue 1 pp. 71-73

Epidermolysis bullosa acquisita: diagnosis by fluorescence overlay antigen mapping and clinical response to high-dose intravenous immunoglobulin

M. Campos

M. Campos

Departments of Dermatology and Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Search for more papers by this author
C. Silvente

C. Silvente

Departments of Dermatology and Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Search for more papers by this author
Manuel Lecona

Manuel Lecona

Departments of Dermatology and Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Search for more papers by this author
R. Suárez

R. Suárez

Departments of Dermatology and Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Search for more papers by this author
P. Lázaro

P. Lázaro

Departments of Dermatology and Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Search for more papers by this author
First published: 07 November 2005
Citations: 20
Dr Minia Campos, Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain.
E-mail: [email protected]

Conflict of interest: none declared.

Summary

Epidermolysis bullosa acquisita (EBA) is a chronic, subepidermal blistering disease characterized by the presence of autoantibodies to type VII collagen, located below the lamina densa of the basement membrane zone (BMZ). There is a large clinical and histological overlap between EBA and other subepidermal autoimmune bullous diseases, therefore, complex immunological techniques are required to make an accurate diagnosis. Therapy of EBA is also a difficult issue. Most patients do not respond to several common immunosuppressive agents. We describe a patient who has shown a good response to high-dose intravenous immunoglobulin therapy.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.